Drug profile · INN
butalbital
BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE
butalbital (BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — butalbital
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
butalbital (BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is butalbital?
butalbital (BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for butalbital?
BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE is a marketed brand name for butalbital. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of butalbital?
butalbital has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.